Nasdaq vktx.

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Nasdaq vktx. Things To Know About Nasdaq vktx.

Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range.Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ...

Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

In the news. Yahoo Finance. 3 days ago. Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.

Viking Therapeutics (NASDAQ:VKTX) spiked in late December, due to recent news indirectly related to the biopharma firm, and its efforts to bring a treatment for non-alcoholic steatohepatitis (or ...NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Forecast & Price Target $11.56 +0.21 (+1.85%) (As of 11/22/2023 ET) Compare Today's Range $11.21 $11.68 50 …SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX.According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.

At September 30, 2021, Viking held cash, cash equivalents and short-term investments totaling $216.1 million, compared to $248.4 million as of December 31, 2020. This concludes my financial review ...

Indeed, Viking Therapeutics (NASDAQ:VKTX) stock is up 246% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...

Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00. Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...Viking Therapeutics said VK2809 met the main goal of a phase 2b trial by showing statistically significant reductions in liver fat in patients with NASH. VKTX +12% yesterday, @CR144 Research ...Fintel reports that on May 16, 2023, BTIG maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of May 11, 2023 ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...24 Jun, 2021, 07:05 ET. SAN DIEGO, June 24, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ...SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell …

Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...Viking Therapeutics, Inc NASDAQ: VKTX is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders.Shares of Viking Therapeutics ( VKTX 6.23%) were up 89.7% for the week as of Thursday afternoon, after being up as much as 95.5% for the week, according to data provided by S&P Global Market ...Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...As at June 2022, Viking Therapeutics had cash of US$169m and no debt. In the last year, its cash burn was US$47m. So it had a cash runway of about 3.6 years from June 2022. There's no doubt that ...VKTX Viking Therapeutics Inc Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021Back to VKTX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stocks In Focus Nabriva's Antibiotic Aces a Late-stage Trial In China. ... (NASDAQ:TVTX) said it received final pre-NDA meeting minutes, ...

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Viking Therapeutics, Inc. (VKTX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Viking Therapeutics, ...Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Fintel reports that on July 27, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 141.43% Upside. As of ...Viking Therapeutics (NASDAQ: VKTX) stock jumped 69% yesterday on news about Phase 1 testing of their weight loss treatment, VK2735. Given the excitement in the market more generally about the new existence of weight loss drugs that really, actually, work we might think this is great.Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a wider loss of 19 cents per share for the first quarter compared to a loss of 13 cents per share a year ago. Analysts, on average, had estimated a ...צפה בגרף ‎Viking Therapeutics, Inc.‎ בזמן אמת כדי לעקוב אחר תנועת מחיר המניה. תמצא תחזיות שוק, ‎VKTX‎ וחדשות שוק כלכליות.Nov 28, 2023 · See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Mar 30, 2023 · Shares of Viking Therapeutics ( VKTX 6.23%) were up 89.7% for the week as of Thursday afternoon, after being up as much as 95.5% for the week, according to data provided by S&P Global Market ...

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...Look at Viking Therapeutics (NASDAQ:VKTX), for example.. This top biotech stock has been rocketing higher on the obesity story thanks to its VK2735 treatment.. Working much like Eli Lilly’s ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...Instagram:https://instagram. highest volume etfsaurozongold royalties stocks5 year u.s. treasury yield Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company. the cheapest place to buy goldchinese etfs Viking Therapeutics Inc (NASDAQ:VKTX). 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today's Change. 3.54. Today|||52-Week Range. 25.72. +38.35%. Year-to- ...Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX) $13.01 +0.79 (+6.46%) (As of 12/1/2023 ET) Today's Range $11.82 $13.10 50-Day Range $9.24 … popular blue chip stocks Viking Therapeutics Earnings & Revenue FAQ. What were VKTX's earnings last quarter? On Oct 25, 2023, Viking Therapeutics (NASDAQ: VKTX) reported Q3 2023 ...hace 12 horas ... Join SI Premium – FREE. Viking Therapeutics (NASDAQ: VKTX) Climbs 13%. The reason for the spike wasn't clear but it may be tied to news Roche ...